Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06038474 · ClinicalTrials.gov registry record · Phase 2
Descartes-08 for Patients With Systemic Lupus Erythematosus
A Phase 2 study of Systemic Lupus Erythematosus (SLE), sponsored by Cartesian Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06038474: Active Phase 2 study of Systemic Lupus Erythematosus (SLE), sponsored by Cartesian Therapeutics.
NCT06038474 is a Phase 2 study of Systemic Lupus Erythematosus (SLE) that is active but no longer recruiting, run by Cartesian Therapeutics. The registered enrollment target is 6 participants, below the 1,064-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06038474, a Phase 2 study of Systemic Lupus Erythematosus (SLE), is active but no longer recruiting, sponsored by Cartesian Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
Primary Outcome
Results will be descriptive. Safety and tolerability endpoints will include descriptive statistics of AEs and SAEs. Patients must be followed until all AEs have resolved to Grade 2 or less except for lymphopenia and alopecia.
Conditions Studied
Interventions
- DRUG Descartes-08
Study Locations (1)
California
- Profound Research LLC - Oceanside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 2 |
What the registry record for NCT06038474 still lists
NCT06038474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,064-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 1 intervention - of which Descartes-08 is the first listed.
NCT06038474 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06038474 about?
NCT06038474 is a clinical study titled "Descartes-08 for Patients With Systemic Lupus Erythematosus". This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
What is the current status of trial NCT06038474?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2024-02-12. Estimated completion is 2026-11-01.
What conditions does trial NCT06038474 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE).
What interventions are being tested in trial NCT06038474?
The interventions under investigation include: Descartes-08 (DRUG).
Who is sponsoring clinical trial NCT06038474?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06038474 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus (SLE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06038474's enrollment target sits among peer trials
6 15th of 14 the lowest of 14 other Systemic Lupus Erythematosus (SLE) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus (SLE) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
COMPLETED · Phase 2
-
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
COMPLETED · Phase 2
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
RECRUITING
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RECRUITING · Phase 1
-
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
RECRUITING · Phase 1
-
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI